Blog

April 25, 2022

Promotional Image

P21 is proud to announce that support for CDISC Open Rules Engine (CORE) is now available in P21 Community 4.0. We have expanded CORE’s reference implementation to let you execute machine-readable CDISC Conformance Rules within the familiar P21 toolkit. This new CDISC Engine can run from the desktop GUI or command-line interface (CLI) on any platform in which you have already installed P21 Community.

Read More
April 25, 2022

As of April 25, 2022, we have released P21 Community 4.0 to general availability! Install it now from our Downloads page.

P21C 4.0 is the first major release of this application since P21's M&A with Certara in October 2021, per the commitment that P21's software applications will “continue to be supported, updated, and developed.”

Read More
March 2, 2022

On December 15th, 2021, the Japanese Pharmaceutical and Medical Devices Agency (PMDA) published its long-awaited update to the validation rules for SDTM, ADAM and Define.xml. PMDA Validation Rules 3.0 introduce additional standard conformance rules from CDISC, support for ADaM-IG 1.1, and many other changes.

At Pinnacle 21, we've got you covered. We have released support for these new rules in our latest validation engine PMDA 2010.2. And in this webinar, we've shared everything you need to know about PMDA Validation Rules 3.0.

Read More
January 4, 2022

On November 29th, CDISC released updated versions of SDTM and ADaM, including standardized structures for medical devices and new non-compartmental analysis data.

Moving to new versions of standards is always a challenge and requires planning. Pinnacle 21's subject matter experts Trevor Mankus and Michael Beers summarized key changes and answered industry questions in this webinar and the discussion below, so you can better prepare to up-version your study data.

Read More
December 20, 2021

New PMDA Engine

Pinnacle 21 is happy to announce the latest Validation Engine for submissions to Japan's PMDA! 🇯🇵

P21 has spent many months developing this Engine with and for the PMDA, and now the industry—whether as users of P21 Community (P21C) or clients of P21 Enterprise (P21E)—can utilize it for expanded standards support, e.g., ADaMIG 1.1, in their eData submissions to the Japanese health agency.

Read More
December 9, 2021

In October, 2021, Pinnacle 21 was successfully acquired by Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation and regulatory science. In this post, we recap P21's founding impetus, share the benefits of joining Certara, and set expectations for the great things to come.

Max and Bill celebrating the closure of their M&A deal

Read More
November 17, 2021

Despite continuous development of, and the quarterly updates to, CDISC Controlled Terminology, there is still a need for study-specific extensions to standard codelists.

Often, extensions to standard terminology are incorrect. For example, some users falsely believe that any new terms can be added to an extensible codelist and related data validation is not needed if new terms are listed in the define.xml. In this webinar, Sergiy Sirichenko will summarize industry metrics across many studies and sponsors to produce an overall picture of CDISC Controlled Terminology utilization. He will review common issues with implementation of controlled terminology and reinforce best practices for extending standard codelists.

Read More
September 10, 2021

SDTM Trial Summary (TS) domain is essential for regulatory submission and is part of FDA rejection criteria.

TS can be complex to implement with guidance spread across SDTMIG, FDA Study Data Technical Conformance Guide (TCG), FDA Technical Rejection Criteria, and numerous terminologies. Interpretation of validation results for TS can also be difficult. In this webinar, Kristin Kelly discusses the minimum set of parameters that should be included in TS and reviews common implementation issues.

Read More
September 10, 2021

The COVID-19 pandemic had an immense impact on people’s lives. The quick development of effective and safe vaccines as well as their availability are critical to public health.

Clinical trials for vaccines typically collect similar types of data. Preparing this data for submission requires knowledge of specific guidance from regulatory agencies and standards development organizations. In this webinar, Michael Beers reviews FDA, PMDA, and CDISC guidance and other considerations for preparing vaccine studies for regulatory submissions. Also, Michael goes over common problems and inconsistencies seen in data of vaccine studies.

Read More
March 3, 2021

Controlled Terminology have you confused? We got you.

When starting a new clinical study and preparing the data collection design, you may ask yourself: How important is Controlled Terminology (CT)? How do I prepare the data collection process to be CDISC compliant and avoid rework for submissions? We often receive questions such as these. Whether you are newer to clinical studies or a seasoned veteran, CT can often be an elusive and confusing topic. Having a better understanding of CT standards and requirements, as well as CT-related issues found in validation checks, can improve your submission data and processes.

Read More

Want a demo?

Let’s Talk.

We're eager to share and ready to listen.

Cookie Policy

Pinnacle 21 uses cookies to make our site easier for you to use. By continuing to use this website, you agree to our use of cookies. For more info visit our Privacy Policy.